MAPK1 and breast carcinoma: However, in view of findings indicating that activated PARP-1 highly augments the activity of ERK in the nucleus even in the absence of DNA damage [3,4], a different therapeutic potential of PARP inhibitors is examined in breast cancer cells lacking BRCA mutations.